期刊文献+

回肠巨大原发性弥漫性大B细胞淋巴瘤合并肠梗阻1例

A Case of Primary Diffuse Large B Cell Lymphoma of the Giant Ileum Complicated with Intestinal Obstruction
下载PDF
导出
摘要 目的:本文旨在探讨回肠巨大原发性弥漫性大B细胞淋巴瘤的临床表现、影像学特点及诊治要点。方法:对延安市人民医院胃肠外科收治的回肠巨大原发性弥漫性大B细胞淋巴瘤合并肠梗阻1例患者进行病例回顾并复习相关文献。结果:回肠巨大原发性弥漫性大B细胞淋巴瘤,发病率低,临床表现不典型;合并肠梗阻者,往往容易误诊及漏诊,最终确诊要需手术探查及病理。结论:回肠原发性弥漫性大B细胞淋巴瘤合并肠梗阻缺乏特异性临床表现,手术为首选治疗方法,需结合手术病理及免疫组化进行确诊。Objective: To explore the clinical manifestations, imaging characteristics, and key points of diagnosis and treatment of giant primary diffuse large B-cell lymphoma in the ileum. Method: A case review and literature review were conducted on a patient with giant primary diffuse large B-cell lymphoma of the ileum and intestinal obstruction admitted to the Department of Gastroenterology at Yan’an People’s Hospital. Results: The large primary diffuse large B-cell lymphoma of the ileum had a low incidence rate and atypical clinical manifestations;Patients with combined intestinal obstruction are often prone to misdiagnosis and missed diagnosis, and the final diagnosis requires surgical exploration and pathology. Conclusion: Primary diffuse large B-cell lymphoma of the ileum with intestinal obstruction lacks specific clinical manifestations, and surgery is the preferred treatment method. Diagnosis should be based on surgical pathology and immunohistochemistry.
作者 程鑫瀚 李盼
出处 《临床个性化医学》 2024年第3期858-862,共5页 Journal of Clinical Personalized Medicine
  • 相关文献

参考文献4

二级参考文献28

  • 1Hyung Soon Park,Yu Jin Kim,Woo Ick Yang,Chang Ok Suh,Yong Chan Lee.Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma[J].World Journal of Gastroenterology,2010,16(17):2158-2162. 被引量:14
  • 2Prasanna Ghimire.Primary esophageal lymphoma in immunocompetent patients:Two case reports and literature review[J].World Journal of Radiology,2010,2(8):334-338. 被引量:8
  • 3林桐榆,张红雨,黄岩,管忠震,沈悌,石远凯,朱军,克晓燕,王华庆,沈志祥,于世英,刘霆,施笑利.R-CHOP与CHOP方案治疗初治弥漫大B细胞型淋巴瘤在中国的多中心随机对照研究[J].癌症,2005,24(12):1421-1426. 被引量:48
  • 4易石坚,李兰兰,钟德玝.成人小肠套叠的临床分析[J].中国普通外科杂志,2007,16(4):400-401. 被引量:5
  • 5Coiffier B, Lepage E. Prognosis of aggressive lymphomas :a study of five prognostic models with patients included in the LNH-84 regimen [J]. Blood, 1989,74(2) :558-564.
  • 6Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 [J]. Blood, 1994,83(2) :435-445.
  • 7Coiffier B, Haioun C, Ketterer N, et al. Rituximab (antiCD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma., a multicenterphase Ⅱ study [J]. Blood, 1998,92(6) : 1927-1932.
  • 8The Non-Hodgkin's Lymphoma Pathologic Classification Project.National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage [J]. Cancer, 1982,49(10) : 2112-2135.
  • 9Tedder TF, Engel P. CD20:a regulator of cell-cycle progression of B lymphocytes [J]. Immunol Today, 1994,15(9):450-454.
  • 10Demidem A,(IDEC-C2B8)lymphoma cellCancer BiotherLam T, Alas S, et al. Chimeric anti-CD20 monoclonal antibody sensitizes a B cell line to cell killing by cytotoxic drugs [J].Radiopharm, 1997, 12(3) : 177-186.

共引文献149

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部